Biotech Receptos files for a $86 million IPO

By
A A A
Share |

Receptos, a biotech with a Phase 3 drug candidate for relapsing multiple sclerosis, filed on Thursday with the SEC to raise up to $86 million in an initial public offering. The San Diego, CA-based company, which was founded in 2008 and has yet to generate any revenue from drug sales, plans to list on the NASDAQ under the symbol RCPT. Receptos initially filed confidentially on February 13, 2013. Credit Suisse, Leerink Swann and BMO Capital Markets are the joint bookrunners on the deal. No pricing terms were disclosed.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks:

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

Most Active by Volume

43,348,260
  • $60.873 ▼ 0.79%
18,610,139
  • $4.265 ▼ 3.51%
17,102,266
  • $3.14 ▼ 0.95%
15,091,014
  • $87.02 ▲ 0.30%
13,534,098
  • $16.3031 ▼ 0.41%
7,999,557
  • $46.54 ▼ 1.88%
7,988,315
  • $563.71 ▲ 7.42%
7,014,297
  • $34.90 ▲ 1.48%
As of 4/24/2014, 10:02 AM